순환종양핵산 검사의 임상 적용

키워드

참고문헌 (82)

1. Mandel P, "Nuclear acids in human blood plasma", C R Seances Soc Biol Fil, 142, pp.241~243 (1948)
2. Leon SA, "Free DNA in the serum of cancer patients and the effect of therapy", Cancer Res, 37, pp.646~650 (1977)
3. Siravegna G, "Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients", Nat Med, 21, pp.795~801 (2015)
4. Ulz P, "Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer", Nat Commun, 7, pp.12008~ (2016)
5. De Mattos-Arruda L, "Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA : a proof-of-principle", Ann Oncol, 25, pp.1729~1735 (2014)
6. Andersson D, "Ultrasensitive circulating tumor DNA analysis enables precision medicine : experimental workflow considerations", Expert Rev Mol Diagn, 21, pp.299~310 (2021)
7. Galarza Fortuna GM, "Circulating tumor DNA: Where are we now? A mini review of the literature", World J Clin Oncol, 11, pp.723~731 (2020)
8. Heitzer E, "Circulating tumor DNA as a liquid biopsy for cancer", Clin Chem, 61, pp.112~123 (2015)
9. Lin C, "Liquid biopsy, ctDNA diagnosis through NGS", Life(Basel), 11, pp.890~ (2021)
10. Wan JCM, "Liquid biopsies come of age : towards implementation of circulating tumour DNA", Nat Rev Cancer, 17, pp.223~238 (2017)
11. Hu Z, "The main sources of circulating cell-free DNA : Apoptosis, necrosis and active secretion", Crit Rev Oncol Hematol, 157, pp.103166~ (2021)
12. Stroun M, "About the possible origin and mechanism of circulating DNA apoptosis and active DNA release", Clin Chim Acta, 313, pp.139~142 (2001)
13. Luger K, "Crystal structure of the nucleosome core particle at 2. 8 A resolution", Nature, 389, pp.251~260 (1997)
14. Bronkhorst AJ, "The emerging role of cell-free DNA as a molecular marker for cancer management", Biomol Detect Quantif, 17, pp.100087~ (2019)
15. Mouliere F, "Enhanced detection of circulating tumor DNA by fragment size analysis", Sci Transl Med, 10, pp.eaat4921~ (2018)
16. Mouliere F, "High fragmentation characterizes tumour-derived circulating DNA", PLoS One, 6, pp.e23418~ (2011)
17. Abbosh C, "Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution", Nature, 545, pp.446~451 (2017)
18. Kamat AA, "Circulating cell-free DNA : a novel biomarker for response to therapy in ovarian carcinoma", Cancer Biol Ther, 5, pp.1369~1374 (2006)
19. Bettegowda C, "Detection of circulating tumor DNA in early-and late-stage human malignancies", Sci Transl Med, 6, pp.224ra24~ (2014)
20. Zhang Y, "Pan-cancer circulating tumor DNA detection in over 10, 000 Chinese patients", Nat Commun, 12, pp.11~ (2021)
21. Grabuschnig S, "Circulating cell-free DNA is predominantly composed of retrotransposable elements and non-telomeric satellite DNA", J Biotechnol, 313, pp.48~56 (2020)
22. Fleischhacker M, "Circulating nucleic acids(CNAs)and cancer —a survey", Biochim Biophys Acta, 1775, pp.181~232 (2007)
23. Meddeb R, "Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA", Clin Chem, 65, pp.623~633 (2019)
24. Shin Saeam, "Clinical Practice Guidelines for Pre-Analytical Procedures of Plasma Epidermal Growth Factor Receptor Variant Testing", Annals of Laboratory Medicine, 42(2), pp.141~149 (2022), 대한진단검사의학회[DOI]
25. El Messaoudi S, "Circulating cell free DNA : Preanalytical considerations", Clin Chim Acta, 424, pp.222~230 (2013)
26. Martignano F, "Cell-free DNA : An overview of sample types and isolation procedures", Methods Mol Biol, 1909, pp.13~27 (2019)
27. Melkonyan HS, "Transrenal nucleic acids : from proof of principle to clinical tests", Ann N Y Acad Sci, 1137, pp.73~81 (2008)
28. Tsui NB, "High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing", PLoS One, 7, pp.e48319~ (2012)
29. Yao W, "Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva : A qualitative study", Gene, 590, pp.142~148 (2016)
30. Bobillo S, "Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas", Haematologica, 106, pp.513~521 (2021)
31. De Mattos-Arruda L, "Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma", Nat Commun, 6, pp.8839~ (2015)
32. Kim Y, "Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy", Cancer Cell Int, 21, pp.50~ (2021)
33. Asano H, "Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay", Clin Cancer Res, 12, pp.43~48 (2006)
34. Azuara D, "Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer", Clin Chem, 58, pp.1332~1341 (2012)
35. Taly V, "Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients", Clin Chem, 59, pp.1722~1731 (2013)
36. Kinde I, "Detection and quantification of rare mutations with massively parallel sequencing", Proc Natl Acad Sci U S A, 108, pp.9530~9535 (2011)
37. Mosele F, "Recommendations for the use of next-generation sequencing(NGS)for patients with metastatic cancers : a report from the ESMO Precision Medicine Working Group", Ann Oncol, 31, pp.1491~1505 (2020)
38. Filipska M, "Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment", Mol Oncol, 15, pp.1667~1682 (2021)
39. Rolfo C, "Liquid Biopsy for Advanced NSCLC : A Consensus Statement From the International Association for the Study of Lung Cancer", J Thorac Oncol, 16, pp.1647~1662 (2021)
40. Litwin MS, "The diagnosis and treatment of prostate cancer : A review", JAMA, 317, pp.2532~2542 (2017)
41. de Bono J, "Olaparib for metastatic castration-resistant prostate cancer", N Engl J Med, 382, pp.2091~2102 (2020)
42. Berruti A, "Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease : predictive role of bone resorption and formation markers evaluated at baseline", J Urol, 164, pp.1248~1253 (2000)
43. Bubendorf L, "Metastatic patterns of prostate cancer : an autopsy study of 1, 589 patients", Hum Pathol, 31, pp.578~583 (2000)
44. Dang HX, "Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer", JCO Precis Oncol, 4, pp.680~713 (2020)
45. Lau E, "Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression", Genome Med, 12, pp.72~ (2020)
46. Shaya J, "Analysis of the prognostic significance of circulating tumor DNA in metastatic castrate resistant prostate cancer", Clin Genitourin Cancer, 19, pp.564~ (2021)
47. 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018", Cancer Research and Treatment, 53(2), pp.301~315 (2021), 대한암학회[DOI]
48. Kim Y, "Overview of the national cancer screening programme and the cancer screening status in Korea", Asian Pac J Cancer Prev, 12, pp.725~730 (2011)
49. Dasari A, "ctDNA applications and integration in colorectal cancer : an NCI Colon and Rectal–Anal Task Forces whitepaper", Nat Rev Clin Oncol, 17, pp.757~770 (2020)
50. Flamini E, "Free DNA and carcinoembryonic antigen serum levels : an important combination for diagnosis of colorectal cancer", Clin Cancer Res, 12, pp.6985~6988 (2006)
51. Luo H, "Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer", Sci Transl Med, 12, pp.eaax7533~ (2020)
52. Tie J, "Serial circulating tumor DNA(ctDNA)and recurrence risk in patients(pts)with resectable colorectal liver metastasis(CLM)", J Clin Oncol, 34(S), pp.e15131~e15131 (2016)
53. Venook AP, "Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer : A randomized clinical trial", JAMA, 317, pp.2392~2401 (2017)
54. Kopetz S, "Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer", N Engl J Med, 381, pp.1632~1643 (2019)
55. Meric-Bernstam F, "Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer(MyPathway) : an updated report from a multicentre, open-label, phase 2a, multiple basket study", Lancet Oncol, 20, pp.518~530 (2019)
56. Tay TKY, "Liquid biopsy in breast cancer : A focused review", Arch Pathol Lab Med, 145, pp.678~686 (2021)
57. Magbanua MJM, "Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival", Ann Oncol, 32, pp.229~239 (2021)
58. Chopra N, "Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer", Nat Commun, 11, pp.2662~ (2020)
59. Rose M, "PARP inhibitors : Clinical relevance, mechanisms of action and tumor resistance", Front Cell Dev Biol, 8, pp.564601~ (2020)
60. Weigelt B, "Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer", Clin Cancer Res, 23, pp.6708~6720 (2017)
61. Cheng ML, "Circulating tumor DNA in advanced solid tumors : Clinical relevance and future directions", CA Cancer J Clin, 71, pp.176~190 (2021)
62. Ballehaninna UK, "The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma : An evidence based appraisal", J Gastrointest Oncol, 3, pp.105~119 (2012)
63. Sivapalan L, "Molecular profiling of ctDNA in pancreatic cancer : Opportunities and challenges for clinical application", Pancreatology, 21, pp.363~378 (2021)
64. Grunvald MW, "Current status of circulating tumor DNA liquid biopsy in pancreatic cancer", Int J Mol Sci, 21, pp.7651~ (2020)
65. Giornelli GH, "Management of relapsed ovarian cancer : a review", Springerplus, 5, pp.1197~ (2016)
66. Asante DB, "Liquid biopsy in ovarian cancer using circulating tumor DNA and cells : Ready for prime time?", Cancer Lett, 468, pp.59~71 (2020)
67. Vargas AN, "Natural history of ovarian cancer", Ecancermedicalscience, 8, pp.465~ (2014)
68. Bogani G, "RECIST 1. 1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy", Eur J Obstet Gynecol Reprod Biol, 237, pp.93~99 (2019)
69. Charkhchi P, "CA125 and ovarian cancer : A comprehensive review", Cancers(Basel), 12, pp.3730~ (2020)
70. Hentze JL, "Searching for new biomarkers in ovarian cancer patients : Rationale and design of a retrospective study under the Mermaid III project", Contemp Clin Trials Commun, 8, pp.167~174 (2017)
71. Asaoka Y, "PD-1 Blockade in tumors with mismatch-repair deficiency", N Engl J Med, 373, pp.1979~ (2015)
72. Georgiadis A, "Non-invasive detection of microsatellite instability and high tumor mutation burden in cancer patients treated with PD-1 blockade", Clin Cancer Res, 25, pp.7024~7034 (2019)
73. Friedlaender A, "Tissue-plasma TMB comparison and plasma TMB monitoring in patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors", Front Oncol, 10, pp.142~ (2020)
74. Qiu P, "Measuring tumor mutational burden(TMB)in plasma from mCRPC patients using two commercial NGS assays", Sci Rep, 9, pp.114~ (2019)
75. Miyazawa H, "Peptide nucleic acid–locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation", Cancer Sci, 99, pp.595~600 (2008)
76. Freidin MB, "Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies", Clin Chem, 61, pp.1299~1304 (2015)
77. Sefrioui D, "Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer", Dig Liver Dis, 47, pp.884~890 (2015)
78. Taniguchi K, "Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas", Clin Cancer Res, 17, pp.7808~7815 (2011)
79. Newman AM, "An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage", Nat Med, 20, pp.548~554 (2014)
80. Gale D, "Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA", PLoS One, 13, pp.e0194630~ (2018)
81. Narayan A, "Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing", Cancer Res, 72, pp.3492~3498 (2012)
82. Dai P, "Calibration-free NGS quantitation of mutations below 0. 01% VAF", Nat Commun, 12, pp.6123~ (2021)

관련 논문AI추천